CatalystFDA/Bio

LILLY WINS FULL FDA APPROVAL FOR INLURIYO COMBO IN BREAST CANCER - SEEKINGALPHA

FDA approval of Lilly's Inluriyo combo for breast cancer signals a regulatory catalyst.

What changed

FDA approval of Lilly's Inluriyo combo for breast cancer signals a regulatory catalyst.

Why it matters

FDA approval of Lilly's Inluriyo combo for breast cancer signals a regulatory catalyst. — impact context not separately stored; see What changed.

Sources